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Abstract A wealth of evidence correlates the chemopreventive
activity of a fiber-rich diet with the production of butyrate. In
order to identify the genes transcriptionally modulated by the
molecule, we analyzed the expression profile of butyrate-treated
colon cancer cells by means of cDNA expression arrays.
Moreover, the effect of trichostatin A, a specific histone
deacetylase inhibitor, was studied. A superimposable group of
23 genes out of 588 investigated is modulated by both butyrate
and trichostatin A. Among them, a major target was tob-1, a
gene involved in the control of cell cycle. tob-1 is also up-
regulated by butyrate in a neuroblastoma-derived cell line, and its
overexpression in the colon cells caused growth arrest. Our
findings represent an extensive analysis of genes modulated by
butyrate and identify completely new effectors of its biological
activities. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Colon cancer is the third most common tumor in the de-
veloped countries and the second leading cause of death from
cancer, a¡ecting men and women equally. Epidemiological
studies indicate that environmental factors are of overwhelm-
ing importance in determining the incidence of this disease: in
particular, attention has been focused on diet [1,2].
Among the dietary habits which have been linked to a de-
creased risk of colon cancers, a number of animal investiga-
tions and epidemiological studies suggests that the intake of
dietary ¢ber has a positive, but still debated, role [3^5].
Although di¡erent mechanisms have been proposed so far,
the protective e¡ect is probably mediated by short-chain fatty
acids, and particularly by butyrate (BuA), produced abun-
dantly during colonic microbial ¢ber fermentation [5].
BuA has been indicated as a homeostatic factor of the
normal colonic mucosa [2]. Moreover, the molecule might
hamper the development of neoplasias by impairing the
growth of transformed cells [2]. As a matter of fact, millimolar
concentrations of BuA, comparable with those occurring in
large bowel, a¡ect cell phenotype in vitro, causing cell division
cycle blockade, di¡erentiation or apoptosis in a number of
transformed cell lines [6^8]. In addition, an inverse association
between tumor size and luminal concentration of BuA has
been observed in chemically induced rat colon cancers [9].
The variety of BuA pharmacological activities prompted
the use of the molecule and its analogs in the treatment of
human diseases, including cancers [10,11], bowel in£amma-
tory pathologies [12], L-thalassemia [13], sickle cell anemia
[14], ornithine transcarbamylase de¢ciency [15], cystic ¢brosis
[16] and X-linked adrenoleukodystrophy [17].
Despite the growing interest on BuA clinical use, the mo-
lecular bases of its e¡ect are so far poorly de¢ned. The mod-
ulation of genome expression, as the consequence of chroma-
tin structure changes, is considered a possible mechanism.
Indeed, BuA induces histone hyperacetylation in numerous
cell systems [18] and inhibits histone deacetylase (HDAC) in
vitro [19]. Whether this modi¢cation represents the main
mechanism of action of BuA on gene transcription is still an
open question, since other BuA e¡ects (i.e. modulation of
histone phosphorylation and DNA methylation) have been
reported [20,21]. However, it must be underlined that the
BuA-induced transcriptional activation of some gene pro-
moters was counteracted by HDAC1 overexpression [22].
The importance of HDAC enzymes in controlling genome
expression has been widely demonstrated. Eight distinct de-
acetylases, belonging to two families, have been characterized
so far; they remove the acetyl moieties from the O-acetamido
groups of lysine residues of H2A, H2B, H3 and H4 histones
at speci¢c chromosomal regions, causing chromatin remodel-
ling and modulation of genome transcription [23]. Moreover,
HDACs have been shown to participate in the transcriptional
machinery as part of the corepressor complexes which directly
hamper transcription of multiple cellular genes [23].
Although the genome e¡ects are relevant in the mechanism
of BuA action, no systematic investigation on the genes di-
rectly regulated by BuA has been so far reported. Moreover, it
has not been clearly established whether the e¡ect of BuA on
gene transcription can be ascribed only to histone hyperace-
tylation or/and to other mechanisms. Very recently, a paper
describing the e¡ect of BuA on gene transcription has been
published [24]. However, the authors did not distinguish be-
tween primary (i.e. due to direct gene modulation) and indi-
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rect (i.e. resulting from the synthesis of new proteins) BuA
e¡ects.
Thereby, we characterized the expression pro¢le of a colon
carcinoma-derived cell line, HT-29, treated, in the presence of
cycloheximide, with BuA at a concentration similar to that
occurring in the large bowel lumen. The methodology em-
ployed is based on cDNA arrays which allow the estimation
of mRNA levels of 588 genes simultaneously. The gene rep-
ertoire modulated by BuA was compared with that of HT-29
cells treated with trichostatin A (TSA), a selective HDAC
inhibitor [23].
2. Materials and methods
2.1. Materials
Anti-GATA-2 rabbit polyclonal antibodies were purchased from
Santa Cruz Biotechnologies (Santa Cruz, CA, USA). The ATLAS
cDNA expression array kit, catalog number 7740-1 was furnished
by Clontech (Palo Alto, CA, USA). The array ¢lters contain 588
spotted cDNAs speci¢c for genes involved into cell division cycle,
signal transduction, stress response, apoptosis, DNA synthesis and
repair, and transcriptional regulation. StrataScript RT-PCR kit was
purchased from Stratagene (La Jolla, CA, USA) [K-32P]dATP (3000
Ci/mmol) was obtained from Amersham, Bucks, UK.
2.2. Cell lines and treatments
HT-29 cell line was obtained from American Type Culture Collec-
tion and grown as reported in [25]. Treatments were performed on
cells at 50% con£uence, and the culture media were changed 24 h
before each experiment. HT-29 cells were incubated with various con-
centrations of sodium BuA or TSA, as indicated in the text. Di¡er-
entiation of HT-29 cells was evaluated by alkaline phosphatase assays,
performed as in [26]. For the cDNA array analysis, the cells were
treated concomitantly with the protein synthesis inhibitor cyclohexi-
mide (36 WM). The neuroblastoma cell line, ACN, was kindly given by
Dr. Mirko Ponzoni, Giannina Gaslini Children’s Hospital, Advanced
Biotechnology Center, Genova, Italy. The cells were grown in RPMI
1640 containing 10% fetal calf serum, 10% non-essential amino acids,
50 U/ml penicillin, and 50 Wg/ml streptomycin. ACN were treated with
BuA as reported in Figs. 2C and 3C.
2.3. cDNA expression array
Total RNA was prepared using the Atlas pure total RNA Isolation
kit (Clontech) following manufacturer’s instructions. For analyzing
gene expression in HT-29 cells, the ATLAS cDNA expression array
(cat. # 7740-1) was employed as described in the user’s manual.
Brie£y, 5 Wg of total RNA were converted into 32P-labelled ¢rst
strand cDNA by means of MMLV reverse transcriptase. Unincorpo-
rated 32P-labelled nucleotides were removed by chromatography on
CHROMA SPIN-200 (Clontech). cDNA fractions of highest activity
were pooled for hybridization to each ATLAS membrane. Equal
amounts of cpm (about 4^5U106 cpm) were employed in each pair
of experiments (control and treated cells). After prehybridization, hy-
bridization with probes and washing, the membranes were sealed in
sample bags and exposed to X-ray ¢lm from 1 to 21 days. Several
expositions were taken to select conditions of the highest signals/back-
ground ratio. Primary array data were acquired by a laser scanner and
the relative intensity of signals was then determined by the NIH
Image 1.61 software. Only signals which di¡ered from the control
at least 2-fold in all the three independent experiments were taken
into consideration. The data in Table 1 were expressed as the mean
of three experiments.
2.4. Northern blotting and reverse transcription-polymerase chain
reaction (RT-PCR) analysis
Total RNA for Northern blot and RT-PCR analyses was prepared
as described above. Northern blot experiments were performed as
described in [27] by loading 20 Wg RNA in each lane. 32P-radiolabelled
probes (for tob-1 and GAPDH genes) were prepared from the respec-
tive cDNA sequences puri¢ed from PCR reactions.
Semiquantitative RT-PCR analyses were carried out as described
in [27]. Primer sequences used for tob-1 and GATA-2 ampli¢cation
were obtained from Clontech, while the primers used for glyceralde-
hyde 3-phosphate dehydrogenase were as in 27. Each experiment
was performed at least in triplicate and, in several cases, in quadru-
plicate.
2.5. Immunoblotting and transfection experiments
Immunoblotting analyses were performed as reported in [25]. Tran-
sient transfections were accomplished by using FuGENE 6, following
manufacturer’s instructions (Roche Molecular Biochemicals, Indian-
apolis, USA). HT-29 cells seeded in a 6-well plate were transfected
with 1 Wg of pMe-hTob [28] or with the empty vector. After 36 h
(about 50% con£uence), cells were labelled for 12 h with 2 WCi/well of
Table 1
Human genes induced by BuA and TSA
GenBank accession number Description Fold induction Function
BuA TSA
M68891 GATA-2 13 þ 2 16 þ 2 transcription factor
D38305 TOB-1 10 þ 1 12 þ 2 cell cycle regulator
D10924 HM89 10 þ 2 10 þ 1 chemokine receptor
D10495 PKCN 10 þ 2 9 þ 1 transduction modulator
X75208 EPH3 8 þ 1 7 þ 1 transduction modulator
U09579 p21Cip1 4 þ 1 5 þ 1 cell cycle regulator
U05340 p55 Cdc 4 þ 1 4 þ 1 cell cycle regulator
X74979 TRKE 3 þ 0.5 4 þ 1 transduction modulator
M11717 HSP70 3 þ 0.8 4 þ 1 stress response
S90469 Cytochrome P450 reductase 3 þ 0.3 3 þ 0.5 detoxication
X67951 PAG 3 þ 0.6 3 þ 0.4 stress response
L25080 RHOA 3 þ 0.7 3 þ 0.2 transduction modulator
L13740 NAK1 3 þ 0.5 3 þ 0.6 transduction modulator
L33264 PISSLRE 3 þ 0.6 3 þ 0.5 cell cycle regulator
U02081 NET1 3 þ 0.5 3 þ 0.4 transduction modulator
M60974 GADD45 3 þ 0.4 3 þ 0.3 cell cycle regulator
J03132 ICAM-1 2 þ 0.2 2 þ 0.2 adhesion molecule
M36717 Placental ribonuclease inhibitor 2 þ 0.2 2 þ 0.2
X79389 GST-theta 1 2 þ 0.1 2 þ 0.2 detoxication
X54079 HSP27 2 þ 0.2 2 þ 0.1 stress response
U24166 EB1 2 þ 0.1 2 þ 0.2 transduction response
HT-29 cells were treated for 5 h with or without 2 mM sodium BuA or 0.3 WM TSA, in the presence of 36 WM cycloheximide. Total RNA
was isolated, retrotranscribed, 32P-labelled and hybridized to the cDNA array representing 588 transcripts for known genes. The signals were
then analyzed by NIH Image 1.61 software and expressed as fold of increase with respect to the untreated cells. Data are means of three di¡er-
ent experiments.
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[3H]thymidine for evaluating the growth rate. Moreover, cell extracts
were prepared for analyzing Tob-1 content by immunoblotting tech-
nique.
3. Results and discussion
BuA has been reported to inhibit the growth and induce
di¡erentiation and/or apoptosis of the colon carcinoma-de-
rived cell line HT-29 [29]. These ¢ndings were also con¢rmed
in our preliminary experiments: cell growth was impaired at
0.5 mM concentration, with 50% inhibition at 2 mM BuA
after 4 days. Moreover, after 3 days of 2 mM treatment, a
20-fold increase of alkaline phosphatase activity was observ-
able (data not shown). In brief, BuA in£uences two pivotal
phenotypical features, growth and di¡erentiation, of HT-29
cells.
In order to identify genes regulated by BuA, we screened its
activity on gene expression by means of cDNA expression
arrays. Furthermore, we compared the ¢ndings obtained
with the e¡ects of a highly speci¢c HDAC inhibitor, TSA,
which is structurally unrelated to BuA.
HT-29 cells were treated with 2 mM BuA or with 0.3 WM
TSA, the most e⁄cacious and non-toxic concentrations of the
molecules [22]. An incubation period of 5 h was selected, since
TSA loses its e¡ects on histone acetylation at longer exposi-
tion times [29]. In addition, all the experiments were per-
formed in the presence of cycloheximide to identify only direct
transcriptional e¡ects and rule out the involvement of de novo
synthesized proteins. Examples of the primary array data,
regarding some genes of interest (see below), are reported in
Fig. 1.
Table 1 shows a summary of the expression pro¢les upon
addition of BuA or TSA to growing HT-29 cells; the fold-
induction values are a mean of three independent experiments.
Among the genes identi¢ed by the arrays, only two, namely
p21Cip1 [22] and hsp70 [30,31], have been previously found as
regulated by BuA. A ¢rst conclusion which might be drawn
from the pro¢les obtained is that both BuA and TSA modu-
late an identical and superimposable set of genes, thus under-
scoring the importance of HDAC inhibition in the BuA e¡ect
on genome transcription.
Only two genes were down-regulated by BuA and TSA,
lactoferrin N gene (2-fold) and MAPKAP kinase gene (3-
fold), while 21 genes were up-regulated. It is noteworthy the
large incidence of gene activation compared to down-regula-
tion, which con¢rms that HDACs function mainly as general
transcriptional corepressors.
As reported in Table 1, several of the genes overexpressed
(tob-1, GATA-2, GADD45, PKCN) control important physio-
logical processes, i.e. cell cycle regulation, signal transduction,
DNA repair and genome transcription. Since these genes have
not been previously related to BuA or to HDACs inhibition,
our ¢ndings furnish a novel evidence of their regulation via
histone acetylation and provide potential insights into new
cellular control mechanisms.
Although our pro¢ling experiments point to a large number
of genes as e¡ectors of BuA and TSA activities, we selected
the two genes mostly induced, namely GATA-2 and tob-1, for
further investigation. In successive studies we will address the
role of the other genes up-regulated by histone hyperacetyla-
tion.
GATA-2 is a nuclear transcription factor belonging to a
family of at least seven members. Although they ¢rst emerged
as candidate regulators of gene expression in hematopoietic
cells [32], GATA proteins were then demonstrated to be in-
volved in a large number of tissutal di¡erentiation processes.
In particular, GATA-2 is required for the expansion of ery-
throid and megakaryocyte precursors [33], the development of
placental throphoblasts [34] and urogenital system [35], and in
pituitary cell type determination [36].
The e¡ect of BuA and TSA on the expression of GATA-2
gene in HT-29 cells was investigated by means of semiquanti-
tative RT-PCR and Western blotting (Fig. 2A,B). The results
Fig. 1. E¡ect of HDACs inhibitors on GATA-2, tob-1 and p21 ex-
pression by cDNA array. HT-29 cells were cultured with 2 mM so-
dium BuA or 0.3 WM TSA for 5 h. Untreated cells are indicated as
Cont. The arrows indicate the signal doublet corresponding to the
relative gene.
Fig. 2. E¡ect of HDACs inhibitors on GATA-2 mRNA and protein
levels. A, B: HT-29 cells were cultured as in Fig. 1. Untreated cells
are indicated as Cont. In the experiments showed in A, cyclohexi-
mide (36 WM) was also added to the culture medium. Then, total
RNA was prepared and analyzed by RT-PCR. The detection of the
ampli¢ed product was carried out by silver staining (A). In the ex-
periments showed in B protein cell extracts were analyzed by immu-
noblotting. C: ACN cells were grown with or without 1 mM BuA.
At the indicated time intervals, cells were harvested and total RNA
was prepared. The ampli¢ed products were separated on 1% agarose
gel and the image was acquired by a Fluor-S MultiImager (Bio-
Rad, Richmond, CA, USA).
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con¢rmed the data obtained by the cDNA array, demonstrat-
ing that GATA-2 gene is not only up-transcribed, but also
e⁄caciously translated to the respective protein. Moreover,
we evaluated the activity of BuA on GATA-2 expression in
a di¡erent cell line, namely the neuroblastoma-derived ACN
cells. As shown in Fig. 2C, the fatty acid induces the expres-
sion of the transcription factor also in these cells. This ¢nding
further strengthens the data obtained on BuA-dependent
GATA-2 up-regulation.
Given the role of GATA-2, its identi¢cation as BuA down-
stream target gene might help in explaining the di¡erentiative
e¡ects of the fatty acid. This could be even more important in
view of the chromosome relaxation which follows BuA treat-
ment. Indeed, BuA could (i) increase the levels of GATA-2
protein and (ii) facilitate the transcriptional activity of
GATA-2-containing complexes.
The other gene analyzed is tob-1, a member of the recently
identi¢ed BTG family whose founder gene, BTG1 (B-cell
translocation gene 1), was ¢rstly cloned near the breakpoint
of a chromosomal translocation associated to a chronic lym-
phocytic leukemia [37]. A wealth of evidence suggests that Btg
proteins may be mediators of multiple anti-proliferative activ-
ities [28,37^40]. Particularly, Tob-1 is involved in the arrest of
cell cycle at G1/S boundary [28,39] and its expression varies
during vertebrate development [40]. It was initially identi¢ed
as a protein speci¢cally interacting with ErbB-2 growth factor
receptor, and thus it might negatively regulate the prolifera-
tive activity of transmembrane protein kinases [28]. Successive
reports showed that Tob-1 also interacts with Caf1 protein, a
component of CCR4 (CCR, carbon catabolite repressor) tran-
scriptional complex [39]. Since Caf1 mutations, like those of
CCR4, a¡ect cell division cycle, DNA repair and UV-sensi-
tivity [38,39], it is highly probable that Tob-1 protein, via
interaction with this transcriptional complex, can regulate
key cell functions. Finally, very recently the direct involve-
ment of tob-1 gene in the control of osteoblastic proliferation
and di¡erentiation has been demonstrated by two di¡erent
approaches. Indeed, mice carrying a targeted deletion of the
tob gene have a greater bone mass resulting from increased
numbers of osteoblasts [41]. Moreover, a gene array analysis
allows the observation of tob-1 up-regulation during osteo-
blast di¡erentiation [42].
In the light of the described biological activities of Tob-1,
its up-regulation by BuA treatment appears particularly intri-
guing, since it may account for the anti-proliferative BuA
e¡ects. So far, the BuA-dependent growth impairment has
been mainly ascribed to the increased expression of p21Cip1,
a cyclin-dependent kinase inhibitor [22]. However, this mech-
anism is strongly challenged by the observation that the
growth of primary ¢broblasts from p213=3 mice is still inhib-
ited by BuA, through a mechanism which also requires the
maintenance of pRb in a hypophosphorylated status [43]. In
this scenario, Tob-1 protein could represent a critical e¡ector
of BuA, acting synergistic with p21Cip1. This is strengthened
by data demonstrating that Tob-1, via interaction with Caf1,
interferes with cyclin-dependent kinases activity causing pRb
hypophosphorylation [39].Fig. 3. E¡ect of HDACs inhibitors on Tob-1 mRNA and protein
levels. A, B: The experiments were as in Fig. 2A,B. In B, HeLa
cells were employed as positive control for Tob-1 protein. C: ACN
cells were grown as in Fig. 2C. RT-PCR was performed as de-
scribed under Section 2 and in Fig. 2C.
Fig. 4. E¡ect of transfection of Tob-1 plasmid on cell proliferation
of HT-29 cells. A: HT-29 cells were transfected with 1 Wg of empty
vector or Tob-1 vector. The proliferation was expressed as percent-
age of [3H]thymidine incorporated with respect of control as de-
scribed in Section 2. The data shown represent the mean þ S.E.M.
of three independent experiments, each performed in duplicate.
B: The Tob-1 content of HT-29 cells transfected with Tob-1 vector
was determined by immunoblotting.
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In order to evaluate this hypothesis, we ¢rst veri¢ed the
cDNA array ¢ndings on tob-1 gene by means of Northern
blot (not reported), RT-PCR and Western blot. As shown
in Fig. 3A,B, BuA and TSA strongly induce the transcription
and translation of tob-1 in HT-29 cells. Moreover, the fatty
acid up-regulates tob-1 expression in ACN cells as soon as 1 h
after the addition of the molecule (Fig. 3C). Afterwards, we
investigated whether Tob-1 overexpression caused growth im-
pairment in HT-29 cells. We transiently transfected tob-1-en-
coding cDNA in the colon cell line and evaluated the e¡ect on
the proliferation rate by estimating the incorporation of
[3H]thymidine into the DNA. A remarkable reduction of the
proliferation rate was evident after transfection (Fig. 4A),
which correlated with an increase of Tob-1 protein (Fig.
4B). Therefore, Tob-1 up-regulation might contribute to ex-
plain the BuA anti-proliferative e¡ect.
In conclusion, this paper reports a study aimed at evaluat-
ing the e¡ect of BuA on gene expression by a cDNA array.
Since BuA induces histone hyperacetylation, our ¢ndings also
allow us to identify genes regulated by an increased degree of
histone acetylation and nucleosome relaxation. The use of
TSA further strengthens our conclusions.
Several of the genes whose expression appears regulated by
HDACs activity control important cellular pathways (like
GADD45 and PKCN). These initial observations need to be
con¢rmed and extended by future investigations. Further-
more, we demonstrated by the array technique and by addi-
tional approaches that two genes, i.e. tob-1 and GATA-2, are
strongly up-regulated by the fatty acid. Neither of them had
been previously taken into consideration to explain the action
of BuA. However, since they both induce growth impairment
and/or di¡erentiation, they can account for the complex phe-
notypical e¡ects of the fatty acid.
Several reports suggest that BuA and its structural analogs
might exert important therapeutical e¡ects, acting both as
non-toxic cytostatic drugs and as gene regulators in the treat-
ment of cancers [9,10], hemoglobinopathies [12,13], cystic ¢-
brosis [16] and other diseases. In this context, our ¢ndings not
only contribute to the elucidation of the molecular e¡ects of
BuA (and its analogs), but also might help in the identi¢ca-
tion of important cellular targets for the development of new
pharmacological strategies.
Acknowledgements: This work was supported in part by the Associa-
zione Italiana per la Ricerca sul Cancro (AIRC) grant and by
MURST (Progetti di Rilevante Interesse Nazionale) grants.
References
[1] Howe, G.R., Benito, E., Castelleto, R., Cornee, J., Esteve, J.,
Gallagher, R.P., Iscovich, J.M., Deng-ao, J., Kaaks, R. and
Kune, G.A. (1992) J. Natl. Cancer Inst. 84, 1887^1896.
[2] Zappia, V., Della Ragione, F., Barbarisi, A., Russo, G.L., and
Dello Iacovo, R., Advances in Nutrition and Cancer II (1999)
Adv. Exp. Med. Biol. 472, Plenum, New York.
[3] Burkitt, D.P. (1971) Cancer 28, 3^13.
[4] Giacosa, A., Filiberti, R., Visconti, P., Hill, M.J., Berrino, F. and
D’Amicis, A. (1993) Adv. Exp. Med. Biol. 348, 85^97.
[5] Perrin, P., Pierre, F., Patry, Y., Champ, M., Berreur, M., Pradal,
G., Bornet, F., Me£ah, K. and Menanteau, J. (2001) Gut 48, 53^
61.
[6] Staiano-Coico, J., Steinberg, M. and Higgins, P.J. (1990) Int. J.
Cancer 46, 733^738.
[7] Hague, A., Manning, A.M., Hanlon, K.A., Huschtscha, L.I.,
Hart, D. and Paraskeva, C. (1993) Int. J. Cancer 55, 498^505.
[8] Schwartz, B., Avivi-Green, C. and Polak-Charcon, S. (1998) Mol.
Cell. Biochem. 188, 21^30.
[9] McIntire, A., Gibson, P.R. and Young, G.P. (1993) Gut 34, 386^
391.
[10] Perrin, P., Cassagnau, E., Burg, C., Patry, Y., Vavasseur, F.,
Harb, J., Le Pendu, J., Douillard, J.Y., Galmiche, J.P. and Bor-
net, F. (1994) Gastroenterology 107, 1697^1708.
[11] Hague, A., Elder, D.J., Hicks, D.J. and Paraskeva, C. (1995) Int.
J. Cancer 60, 400^406.
[12] Harig, J.M., Soergel, K.H., Komorowski, R.A. and Wood, C.M.
(1989) N. Engl. J. Med. 320, 23^28.
[13] Perrine, S.P., Ginder, G.D., Faller, D.V., Dover, G.H., Ikuta, T.,
Witkowska, H.E., Cai, S.P., Vichinsky, E.P. and Olivieri, N.F.
(1993) N. Engl. J. Med. 328, 81^86.
[14] Faller, D.V. and Perrine, S.P. (1995) Curr. Opin. Hematol. 2,
109^117.
[15] Maestri, N.E., Brusilow, S.W., Clissold, D.B. and Bassett, S.S.
(1996) N. Engl. J. Med. 335, 855^859.
[16] Rubenstein, R. and Zeitlin, P.L. (1998) Am. J. Respir. Crit. Care
Med. 157, 484^490.
[17] Kemp, S., Wei, H.M., Lu, J.F., Braiterman, L.T., McGuinness,
M.C., Moser, A.B., Watkins, P.A. and Smith, K.D. (1998) Nat.
Med. 4, 1261^1268.
[18] Sealy, L. and Chalkley, R. (1978) Cell 14, 115^121.
[19] Aviram, A., Zimrah, Y., Shaklai, M., Nudelman, A. and Rephae-
li, A. (1994) Int. J. Cancer 15, 906^909.
[20] Bo¡a, L.C., Gross, R.J. and Allfrey, V.G. (1981) J. Biol. Chem.
256, 9612^9621.
[21] De Haan, J.B., Gevers, W. and Parker, M.L. (1986) Cancer Res.
46, 713^716.
[22] Archer, S.Y., Meng, S., Shei, A. and Hodin, R.A. (1998) Proc.
Natl. Acad. Sci. USA 95, 6791^6796.
[23] Struhl, K. (1998) Genes Dev. 12, 599^606.
[24] Mariadason, J.M., Corner, G.A. and Augenlicht, L.H. (2000)
Cancer Res. 60, 4561^4572.
[25] Della Ragione, F., Russo, G.L., Oliva, A., Mastropietro, S.,
Mancini, A., Borrelli, A., Casero, R.A., Iolascon, A. and Zappia,
V. (1995) Oncogene 10, 827^834.
[26] Le Bivic, A. and Arsanto, J.P. (1987) Biol. Cell 60, 41^47.
[27] Iolascon, A., Giordani, L., Moretti, A., Tonini, G.P., Lo Cunso-
lo, C., Mastropietro, S., Borriello, A. and Della Ragione, F.
(1998) Pediatr. Res. 43, 139^144.
[28] Matsuda, S., Kawamura-Tsuzuku, J., Ohsugi, M., Yoshida, M.,
Emi, M., Nakamura, Y., Onda, M., Yoshida, Y., Nishiyama, A.
and Yamamoto, T. (1996) Oncogene 12, 705^713.
[29] Siavoshian, S., Segain, J.P., Kornprobst, M., Bonnet, C., Cher-
but, C., Galmiche, J.P. and Blottiere, H.M. (2000) Gut 46, 507^
514.
[30] Garcia-Bermejo, L., Vilaboa, N.E., Perez, C., Galan, A., De
Blas, E. and Aller, P. (1997) Exp. Cell Res. 236, 268^274.
[31] Gibson, P.R., Rosella, O., Wilson, A.J., Mariadason, J.M., Rick-
ard, K., Byron, K. and Barkla, D.H. (1999) Carcinogenesis 20,
539^544.
[32] Orkin, S.H. (1992) Blood 80, 575^581.
[33] Mouthon, M.A., Freund, M., Titeux, M., Katz, A., Guichard, J.,
Breton-Gorius, J. and Vainchenker, W. (1994) Blood 84, 1085^
1097.
[34] Ma, G.T., Roth, M.E., Groskopf, J.C., Tsai, F.Y., Orkin, S.H.,
Grosveld, F., Engel, J.D. and Linzer, D.I.. (1997) Development
124, 907^914.
[35] Zhou, Y., Lim, K.C., Onodera, K., Takahashi, S., Ohta, J.,
Minegishi, N., Tsai, F.Y., Orkin, S.H., Yamamoto, M. and En-
gel, J.D. (1998) EMBO J. 17, 6689^6700.
[36] Dase, J.S., O’Connel, S.M.O. and Rosenfeld, M.J. (1999) Cell 97,
587^598.
[37] Rouault, J.P., Rimokh, R., Tessa, C., Paranhos, G., Ffrench, M.,
Duret, L., Garoccio, M., Germain, D., Samarut, J. and Magaud,
J.P. (1999) EMBO J. 11, 1663^1670.
[38] Rouault, J.P., Prevot, D., Berthet, C., Birot, A.M., Billaud, M.,
Magaud, J.P. and Corbo, L. (1998) J. Biol. Chem. 273, 22563^
22569.
[39] Ikematsu, N., Yoshida, Y., Kawamura-Tsuzuku, J., Ohsugi, M.,
FEBS 24960 14-6-01
F. Della Ragione et al./FEBS Letters 499 (2001) 199^204 203
Onda, M., Hirai, M., Fujimoto, J. and Yamamoto, T. (1999)
Oncogene 18, 7432^7441.
[40] Holland, N.D., Zhang, S.C., Clark, M., Panopoulou, G., Leh-
rach, H. and Holland, L.Z. (1997) Dev. Dyn. 210, 11^18.
[41] Yoshida, Y., Tanaka, S., Umemori, H., Minowa, O., Usui, M.,
Ikematsu, N., Hosoda, E., Imamura, T., Kuno, J., Yamashita,
T., Miyazono, K., Noda, M., Noda, T. and Yamamoton, T.
(2000) Cell 103, 1085^1097.
[42] Beck Jr., G.R., Zerler, B. and Moran, E. (2001) Cell Growth
Di¡er. 12, 61^83.
[43] Vaziri, C., Stics, L. and Faller, D.V. (1998) Cell Growth Di¡er.
9, 465^474.
FEBS 24960 14-6-01
F. Della Ragione et al./FEBS Letters 499 (2001) 199^204204
